Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Efficacy Objectives Induction Phase • To evaluate the efficacy of etrolizumab dose regimens compared with placebo in inducing CDAI remission, defined as a CDAI score < 150 at the end of the Induction Phase (Week 14) Maintenance Phase • To evaluate the efficacy of etrolizumab compared with placebo in maintaining corticosteroid (CS)-free CDAI remission for 1 year (52 weeks) among patients who achieved sustained CDAI remission at the end of the Induction Phase (Weeks 10 and 14) Safety Objectives • To evaluate the overall safety and tolerability of etrolizumab compared with placebo during Induction and Maintenance Phases of therapy
Critère d'inclusion
- Crohn’s Disease